Growth Hormone Deficiency

Burosumab Significantly Improves Symptoms in Children With X-Linked Hypophosphatemia

A study including 61 children (aged 1 to 12 years) with X-lined hypophosphatemia showed significantly greater clinical improvements in disease-related symptoms, including rickets severity, growth, and biochemistry panels, among those treated with burosumab (Crysvita®) compared with those continuing conventional therapy with oral phosphate and active vitamin D.1 By week 40,...